Physiomics Regulatory News (PYC)

27 October 2022

Physiomics plc

("Physiomics") or ("the Company")

Annual Report and AGM Notice

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it will today publish on its website its Annual Report and Accounts for the financial year ended 30 June 2022, together with its Notice of Annual General Meeting ("AGM"). Shareholders will be sent either printed copies of these materials or a letter notifying them that they are available on the Company's website, depending on the preferences they have expressed to the Company's registrar.

As announced on 29 September 2022, the Company's AGM will be held at 10.00 a.m. on 22 November 2022, at the Company's registered office, The Magdalen Centre, Oxford Science Park, Robert Robinson Avenue, Oxford, OX4 4GA. 

The Company intends to hold a physical AGM this year. In the event that any changes to the 2022 AGM become unavoidable, however, we will announce them on the Company's website at www.physiomics.co.uk. 

A copy of the Notice of AGM, containing further details of the resolutions, as well as a copy of the Company's Annual Report and Accounts will be made available today on the Company's website at www.physiomics.co.uk/investors/reports-prospectus/.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.